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Background: There are no published data on real-life clinical experience comparing inhaled antibiotic therapy via new rapid delivery systems with
nebulised antibiotic therapy in CF. This real world study compares safety, effectiveness and tolerability using tobramycin inhaled powder (TIP)
versus tobramycin inhaled solution (TIS).
Methods: Adult patients with CF commencing TIP (n = 78) completed a questionnaire assessing safety, efﬁcacy, tolerability, patient-satisfaction and
self-reported adherence to TIS at baseline and during 12 months of TIP therapy. FEV1% predicted and exacerbation rate were recorded at each visit.
Results: There was a signiﬁcant improvement in adherence scores, with a signiﬁcant decrease in the number of intravenous antibiotic courses
received during 12 months of TIP compared with the preceding 12 months using TIS. 94% of patients who had previously used TIS preferred TIP
therapy over TIS.
Conclusions: Inhaled powder tobramycin in CF is associated with improved adherence, tolerability and decreased exacerbation rates compared to
nebulised treatment in real-life practice.
© 2014 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.1. Introduction
Progressive respiratory failure due to recurrent respiratory
tract infection caused by Pseudomonas aeruginosa is the most
common cause of morbidity and mortality in people with CF
[1–3]. Advances in therapy over the last 20 years have resulted
in dramatic improvements in median survival [4,5], but also in
a significant increase in the treatment burden of people with
CF. The development of nebulised anti-pseudomonal antibiotic
therapy represents one of the most important advances and☆ Data from this study was presented as a poster presentation at the ECFS
2013, Lisbon, June 2013(1).
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1569-1993/© 2014 European Cystic Fibrosis Society. Published by Elsevier B.V. Ais an important therapeutic option for people with CF who
are chronically infected with P. aeruginosa [6] resulting in
improved quality of life [7], improved lung function [8],
decreased hospitalisations [9], and decreased mortality [10].
However, this twice-daily regimen constitutes a significant
portion of the CF patient's treatment burden as administration
time is approximately 15 min per dose excluding time for
cleaning and disinfection of the delivery device (approximately
20 min per use) [11]. In adults with CF, perceived treatment
burden is highly associated with the number of nebulised
medications prescribed [12]. High treatment burden has been
demonstrated in children [13] and adults [12] with CF—adult
subjects reported spending an average of 108 min (SD ±
58 min) on daily CF treatments—and is associated with a
reduction in adherence with therapies, particularly in adoles-
cents and adults trying to balance family, work, education, and
other responsibilities with the management of their diseasell rights reserved.
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single most important cause of treatment failure [14]. Rates of
adherence vary depending on the intensity and complexity of
the prescribed treatment and on the measure of adherence used.
Adherence rates for all therapies amongst CF [15] and non-CF
[16] paediatric patients have been reported to be below 50%,
while adherence rates for all therapies amongst adults with CF
have been reported at 65% [17]. Adherence to nebuliser therapy
has been reported as 65–80% via self-reporting, 50–60% via
clinician reporting, and 36% via electronic download [18,19].
With the number of treatment options available to people
with CF likely to increase, it is imperative that new therapies
are designed with a view to minimizing or reducing their
impact on treatment burden and, therefore, potential impact on
adherence. A recent Phase III clinical trial [20] comparing a
novel inhaled powder antibiotic delivery system (tobramycin
inhaled powder, TIP) to the established inhaled solution (or
nebulised) delivery system (tobramycin inhaled solution, TIS)
demonstrated similar efficacy and safety profiles for both
methods over a 6-month study period with a significantly
reduced administration time for the inhaled powder delivery
system (mean: 5.6 versus 19.7 min).Treatment satisfaction was
significantly higher for the inhaled powder delivery system
with regard to perceived effectiveness, convenience, and global
satisfaction. However, the rate of cough suspected to be study
drug related was higher in TIP-treated patients (TIP: 25.3%;
TIS: 4.3%), as was the overall discontinuation rate (TIP: 26.9%;
TIS: 18.2%). Another clinical trial showed non-inferiority and
increased patient satisfaction with a different dry powder inhaler
compared to traditional nebulised therapy in adults with CF [21].
An observational study comparing delivery of tobramycin
inhaled solution (TIS) via a more rapid E-Flow delivery system
and a traditional, slower delivery system showed no difference in
lung function, with decreased treatment burden and increased
patient satisfaction using the more rapid system [22]. To date,
there is no published data on real-life experience comparing TIP
therapy with TIS therapy in CF. We hypothesise that use of a
rapid inhaled powder antibiotic delivery system in a real world
clinical setting will reduce treatment burden and increase
adherence in adult patients with CF. In a prospective study we
document safety, effectiveness, adherence and tolerability in a
cohort of CF adults receiving tobramycin inhaled powder (TIP)
112 mg twice daily and compare this with tobramycin inhaled
solution (TIS) 300 mg twice daily.2. Methods
2.1. Subjects
Adult CF patients attending the Cork Adult CF Centre
commencing TIP were recruited from November 2011 and
prospectively analysed up to April 2013. All participants
16 years or greater (as per guidelines for transition at our
centre) who were chronically infected with P. aeruginosa as per
the Leeds criteria [23] were offered TIP therapy, as part of “best
practice” clinical care based on the clinical trial data showingsimilar efficacy and safety profiles, reduced administration time
and higher treatment satisfaction with TIP compared to TIS.2.2. Study design
At baseline visit, retrospective review of all participants'
medical notes over a 12-month period was performed to assess
previous use of TIS, exacerbation rate (measured by the number
of intravenous antibiotic courses received), along with gender,
age, and genotype. A supervised trial dose of TIP therapy was
administered in the CF Centre with spirometry pre- (baseline)
and post- the trial dose using the CareFusion MicroLab™
Spirometer, which is regularly calibrated. If a patient presented
for a routine visit while experiencing an infective exacerbation,
standard treatments for an infective exacerbation were institut-
ed, with the patient asked to return after 2 weeks of treatment
for re-assessment, where possible. If the patient had returned to
their baseline symptomatically at the return visit, questionnaire
and spirometry were performed and these values were used as
the value for the index visit. Patients were reminded at each
interview to give their answers to the questionnaire based on
their symptoms over the whole 3-month period and not just the
most recent period preceding the visit, particularly if this period
included an infective exacerbation. Participants who experi-
enced symptoms of bronchospasm or demonstrated ≥10%
drop in the % predicted FEV1 received 400 μg of salbutamol
via a large volume spacer and spirometry was repeated after
15 min to examine for reversibility. Participants who did not
experience resolution of their symptoms or demonstrate
reversibility post-bronchodilator were excluded and did not
commence TIP therapy.2.3. Patient assessment
All participants completed a questionnaire (a modified version
of the questionnaire used in the phase III clinical trial [20])
assessing safety, effectiveness, tolerability, patient satisfaction
and self-reported adherence to TIS at baseline visit, and at 3, 6, 9
and 12 months of TIP therapy. Participants were asked to record
their cough as no cough (score = 0), mild (score = 1), moderate
(score = 2) or severe (score = 3) and a cough score was recorded
at all time points. Adherence was recorded as excellent (N80%
adherence to therapy, score = 3), moderate (50–80% adherence
to therapy, score = 2), or poor (b50% adherence to therapy,
score = 1) by patient self-reporting using a modified version of
a previously described self-report adherence assessment tool
[19]. FEV1% predicted and exacerbation rate—measured by
the number of intravenous antibiotic courses received since
previous visit—was recorded at each time-point. If a change of
intravenous antibiotics was deemed clinically necessary, this was
counted as a separate course of antibiotics. Study visits were
included if they occurred at a time point +/−4 weeks from the
scheduled visit. If a visit occurred outside of this time point and
not within 4 weeks of another time point, it was considered a
missed visit.
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Chi-square, Mann–Whitney U and Wilcoxon signed rank
testing were used to compare self-reported adherence and cough
scores, exacerbation rates, (calculated as the number of courses of
intravenous antibiotics) and FEV1% predicted between partici-
pants taking TIS therapy (12-month retrospective data) to those
who completed 12-months of TIP therapy (12-month prospective
data).
2.5. Ethical approval
As this real world monitoring measured the response to
changes in standard clinical practice prospectively and routinely
in CF clinics, an ethics waiver was granted by the Clinical
Research Ethics Committee of the Cork Teaching Hospitals.
3. Results
3.1. Demographics
All eligible patients who attended the Cork Adult Cystic
Fibrosis Centre during the study period were offered TIP therapy.
A total of 78 patients were recruited (see Table 1 and Fig. 1).
51/78 (65%) of these were using TIS at time of recruitment.
Prospective 6-month, 9-month and 12-month data was obtained
for 39, 31 and 40 patients respectively (see Fig. 1). The missing
data at 6-, 9-, and 12 months relates to missed collection of data
due to patient non-attendance at routine clinic visit. One patient
died during the observation period. This death occurred in aTable 1
Baseline patient demographics of patients at baseline.
Variable n = 78
Median age in years (range) 26.3 (16–56)
Male gender 46 (59%)
Median FEV1% predicted (IQR) 63.5 (45.5–74)
Genotype: Class I–III mutation 73 (94%)
Use of TIS at baseline 51 (65%)
Self-reported cough score of TIS users (n = 51)
0 19
1 28
2 2
3 2
Self-reported adherence score of TIS users (n = 49)
1 12
2 15
3 22
No. of IVAB courses received in previous
12 months using TIS (n = 50)
0 courses 22
1 course 10
2 courses 7
≥3 courses 11
No. of IVAB courses received in previous
12 months in patients not using TIS (n = 50)
0 courses 14
1 course 7
2 courses 1
≥3 courses 3patient with advanced CF lung disease and was deemed to be
unrelated to TIP therapy. One patient received a lung transplant,
and 3 were lost to follow up, leaving a total of 73 patients.
3.2. Safety
All patients tolerated a supervised trial of TIP therapy. No
patient demonstrated N10% reduction in FEV1% predicted
post-inhalation. 1 patient showed a 9% reduction in FEV1
during his trial of TIP therapy but did not report symptoms
suggestive of bronchospasm. This patient received 400 mcg of
inhaled salbutamol via spacer device with return of FEV1%
predicted to baseline value and has subsequently tolerated TIP
therapy over 6 months.
3.3. Tolerability
10/73 (14%) discontinued TIP over a 6 month period, with all
participants discontinuing TIP therapy within one month of
commencement. Of these, 9/10 discontinued due to broncho-
spasm or cough, while 1/10 discontinued due to haemoptysis
(this patient stopped all inhaled therapies after one month of TIP).
4/10 were previously intolerant of TIS due to bronchospasm or
cough. 4/10 had tolerated TIS previously and successfully
recommenced TIS. 2/10 were commenced on TIS de novo after
discontinuing TIP.
There was no significant difference seen in reported cough
scores in participants at baseline (n = 51), 6 months (n = 39),
9 months (n = 31) and 12 months (n = 40) (p = 0.408). In a
paired subgroup analysis (n = 28) of patients who previously
used TIS comparing cough score at baseline versus cough score
at 12 months there was no significant difference in reported
cough between patients at baseline in the TIS group and
repeated measures in the same patients in the TIP group at
12 months (p = 0.617).
2/78 patients reported previous dysphonia on TIS with 1
patient reporting transient self-limiting dysphonia in the TIP
group. 1/78 patients reported previous dysguesia on TIS with 2
patients reporting transient self-limiting dysguesia in the TIP
group. 2 patients developed oral candidiasis, which responded
to standard anti-fungal treatment and improved oral hygiene.
49/51 (96%) patients who were using TIS at study entry
preferred TIP at all recorded time points citing “time-saving”
and “convenience” compared to TIS as the most common
reasons. Both patients who stated a preference for TIS at
12 months had preferred TIP at 6 months (no 9-month data was
available for either patient).
3.4. Effectiveness
3.4.1. Adherence
There was a significant improvement in adherence scores at
baseline on TIS compared to adherence scores at 3 months,
6 months, 9 months and 12 months using TIP (p = 0.002).
Fig. 2 shows the adherence scores reported at each time point
for all patient visits. The proportion of subjects reporting
excellent adherence was higher across all time points using TIP
Fig. 1. Flow diagram of tobramycin inhaled powder use.
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at study entry. 1 patient reported taking TIP once daily instead
of twice daily. This patient's data was included in the study and
was recorded as “poor” (b50%) adherence according to the
questionnaire criterion regarding adherence.
Subgroup analysis was performed after the first 40 patients
completed 12 months of TIP therapy. 28 of the 40 patients who
completed 12 months of TIPwere using TIS at study entry. 33/40
(83%) reported excellent adherence to TIP at 12 months. 12/28
(43%) who were using TIS at baseline reported excellent
adherence to TIS. In a paired subgroup analysis (n = 28)
comparing adherence scores at baseline to adherence scores at
12 months there was a significantly improved self-reported
adherence score in patients who completed 12 months of TIP12
3
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Fig. 2. Self-reported adherence score for all patient visits.when compared with adherence scores in the same patients at
baseline using TIS (Z score = −2.95, p = 0.003). Fig. 3 shows
the change from baseline adherence at 6 months, 9 months, and
12 months in participants with paired data at these time points.
41% (n = 29) participants reported an improvement in adherence
at 6 months, while 50% reported an improvement in adherence
score at 9-months (n = 11) and 12 months (n = 14).3.4.2. Intravenous antibiotic use
There was a statistically significant decrease in the number
of intravenous antibiotic courses received in participants after
12 months of TIP (median 0 {IQR 0–1}) compared with the
number of courses of intravenous antibiotics received by the
same participants during the preceding 12 months (median 0
{IQR 0–1}) (n = 40) (p b 0.001). Paired analysis in a
subgroup using TIS at baseline (median 0.5, {IQR 0–1.75})
who completed 12-month follow-up on TIP (n = 28) (median
0, {IQR 0–1.0}) showed a statistically significant reduction in1
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Fig. 3. Change from baseline adherence score in patients with longitudinal data
at 6, 9, and 12 months.
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Fig. 4. Number of intravenous antibiotic courses received in 12 months
retrospectively during TIS vs. 12 months prospectively during TIP.
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therapy (p = 0.003). 75% (n = 30) of participants required
no intravenous antibiotics prospectively during 12 months
of TIP compared with 44% (n = 22) of participants in the
preceding 12 months retrospectively on TIS (p b 0.001) (see
Fig. 4). 27 patients were TIS-naïve on study entry. Retrospec-
tive analysis showed that in the year prior to study entry, 14/27
patients in the TIS-naive group required no IVABs, 7 patients
required 1 course, 1 patient required 2 courses and 3 patients
required ≥3 courses. 2 patients had no recorded data. 10/27
study participants had paired data showing IVAB requirements
prospectively during 12 months of TIP therapy. In these 10
patients, 9 patients required no IVABS and 1 patient required 3
courses of IVABs. 4 of the 10 patients who had paired data
available showed a reduction in the number of courses of
IVABs required during 12 months of TIP, and the other 6
patients required the same number of courses in both periods.3.4.3. Lung function
Lung function was stable at all time points with no
significant difference between FEV1% predicted at baseline
(median 63.5 {IQR 45.5–74}) compared with FEV1% predict-
ed after 12 months of TIP (median 66 {IQR 51.25–77.75}) in
all study participants (Z = −1.23, p = 0.217). Paired analysis in
a subgroup using TIS at baseline (median 68, {IQR 52.5–79})
who completed 12-months of TIP (median 66, {IQR 51.25–
77.5}) (n = 28) showed no significant difference in FEV1%
predicted (p = 0.567).3.4.4. TIS-naïve patients
There was also no significant difference in the median
number of intravenous antibiotic courses (p = 0.158) or change
in FEV1% predicted (p = 0.98) between baseline TIS-users and
TIS-naive patients after 12 months of TIP (data not tabulated).
27/78 (35%) were not using TIS at baseline. 12/27 were
self-reported non-adherent to prescribed TIS, 6/27 were never
prescribed TIS, and 9/27 were documented non-tolerant of
TIS-8 due to cough or bronchospasm and 1 due to dysphonia.
9/12 non-adherent to prescribed TIS at baseline reported
adherence to TIP therapy during the study (5 at 12 months, 2 at
9 months, 1 at 6 months, and 1 at 3 months). All 6 who were
never prescribed TIS reported adherence to TIP. In the 9/27
who were non-tolerant of TIS, 5/9 (55%) tolerated TIP therapy,while 4/9 (45%) discontinued TIP within 2 weeks secondary to
cough.
4. Discussion
While most of the existing data regarding inhaled therapies
in CF have been derived from studies using clinical trial
designs [8,24,25], this study describes the effectiveness of
inhaled antibiotics in people with CF in a real world setting and
falls into the category of Comparative Effectiveness Research
(CER). CER involves “studying the effectiveness of an
intervention in routine clinical practice to assist consumers,
clinicians, purchasers, and policy makers to make informed
decisions that will improve health care at both the individual
and population levels” (Committee on Comparative Effective-
ness Research Prioritization, Institute of Medicine). Clinical
trials can only describe the efficacy of an intervention, i.e.
whether the intervention works or not under optimal conditions,
and may not demonstrate the effectiveness of an intervention in
the real world. In particular, interpreting adherence data from
clinical trials is difficult as adherence to the trial intervention by
the participant is a prerequisite for continued involvement in
the trial in most instances. While it has been postulated that the
use of a more rapid delivery system would result in increased
adherence to a given therapy, this is the first study comparing
the effectiveness of the same inhaled antibiotic using 2 different
delivery systems in patients with CF.
The proportion of participants reporting “excellent adher-
ence” in our study almost doubled after transition to TIP (43%
to 83%) This finding further supports data regarding the
existence of suboptimal adherence to nebulised therapy in
people with CF [18]. This is important given a recent study that
demonstrated that high TIS adherence (≥ to 4 cycles per year)
showed a decreased risk of hospitalisations when compared to
poor TIS adherence (≤ to 2 cycles per year) [26]. While it is
important that we continue to develop beneficial therapies for
our patients, it is equally important that we recognise the
potential for a patient to become less adherent as treatment
burden increases. Rapid delivery of therapies via inhaler can
address this issue and may represent the future of inhaled
antibiotics in CF.
Our study demonstrated a statistically significant reduction
in the number of intravenous antibiotic courses received using
inhaled antibiotic therapy prospectively, over a 12-month
period, compared with a 12-month period retrospectively
using traditional nebulised therapy. Reducing the rate of
pulmonary exacerbations is a key objective for CF clinicians.
Recently published data suggests that patients with CF who
experience frequent pulmonary exacerbations are at an
increased risk of experiencing a decline in their lung function
by 5% from baseline and that frequent pulmonary exacerba-
tions are associated with an increased 3-year risk of death or
lung transplant [27]. Up to 15% of adult [28] and 23% of
paediatric [29] patients fail to recover to within 95% of baseline
FEV1% predicted after a pulmonary exacerbation. We suggest
that the decreased exacerbation rate seen after commencement
of the faster delivery system may represent a downstream effect
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increased adherence to a less burdensome treatment regime. We
chose to use intravenous antibiotic usage as a marker of
exacerbation rate because the receipt of intravenous antibiotic
therapy requires review by a clinician in the Cork Adult CF
Centre. In our study population, patients could potentially
access oral antibiotics without such a review. Of note, analysis
of oral antibiotic usage comparing usage for a 12-month period
retrospectively and 12-month period prospectively using TIP
showed no significant difference between the cohorts.
While we do not demonstrate an improvement in lung
function, there is no significant difference in lung function seen
during the study period. The majority of our participants were
not tobramycin-naive at the time of study entry and so the effect
of increased adherence to a more rapid delivery system on lung
function may only become apparent over a longer period of
follow-up. Demonstrating improvements in lung function in
progressive lung disease can be difficult and may be beyond the
scope of this type of study design.
We observed a lower discontinuation rate in our study
compared with that seen in the clinical trial [20] (14% vs. 27%).
This difference may be explained by the fact that 36% of those
who discontinued in the clinical trial did so due to withdrawal
of consent or protocol violation, factors that were not relevant
to our real world study. We reported discontinuation rates for
the first 6-months of therapy to allow a valid comparison with
the clinical trial, in which 6-month discontinuation data was
also reported.
We reported de novo oral candidiasis in 2 participants. Both
cases resolved with first-line anti-fungal therapy allowing
successful recommencement of inhaled therapies. One of the
patients was taking concomitant inhaled corticosteroid therapy,
while the other was using a short-acting beta-agonist inhaler on
an “as required” basis. Oral candidiasis has not previously been
reported as an adverse event associated with use of TIP.
However, both of these patients were not TIS naïve suggesting
the possibility of a drug delivery system-related phenomenon.
The occurrence of oral candidiasis may signify the importance
of good oral hygiene when using dry powder inhaled therapies
with high deposition rates in the oropharynx [30].
5. Conclusion
Our real-world data strongly support the clinical trial data
regarding the effectiveness of TIP therapy, and highlight the
potential for a reduction in treatment burden to impact on health
outcomes.
6. Limitations
Our study had a number of limitations. There is a possibility
that patient preference for TIP and the improved adherence
scores demonstrated in our study result from, or are at least
amplified by, a “honeymoon effect” where the initial period of
use of any new therapy is associated with increased enthusiasm
by the patient for the therapy. However, this effect is likely to
be minimised over time and we did not see any waning ofadherence scores through the study period with adherence
scores maintained in those on TIP therapy for 12 months.
A limitation of real world studies is that one cannot
guarantee complete data collection at all time points in
individual participants. However, in 40 patients we have paired
data at baseline and (at least) 12 months allowing longitudinal
comparison over a 12-month period in this subgroup.
The measurement of adherence in any study is difficult. Our
study measured adherence by patient self-report, a method which
has been shown to overestimate adherence to therapy in a CF
population [18]. To minimise this effect, the questioning was
carried out by a CF research nurse and not a clinician from the
patients clinical care team. Care was taken to ensure that the
self-reported adherence question was worded so as to ask about
the “use” of TIP and so did not use the word adherence or any
other terminology which may not have been understood by study
participants. Patients were questioned specifically regarding their
use of the inhaled tobramycin device as prescribed by the
patient's clinician, without reference to any other treatments.
Patients were encouraged to be honest at the time of questioning
regarding their adherence and assured that the information given
by them as part of this study would not be used by their clinician
in the course of their routine clinical care. The relatively low level
of self-reported adherence to TIS at study entry (43%), which
approaches that seen in studies using electronic feedback
monitors and prescription refill studies, may reflect a limited
effect of responder bias in our study.
There is also potential for recall bias with regard to patient's
recall of their adherence with therapy. This may be more
marked for recall of adherence during the 12-month period of
TIS therapy at study entry compared with recall of adherence
during the 3-month periods between study visits while on TIP
therapy. However, the reduction in intravenous antibiotic usage
demonstrated in the patients who reported improved adherence
would support the existence of a genuine improvement in
adherence in this group.References
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